O2h Ventures

What O2h Ventures does

O2h Ventures Limited is a UK-based, FCA-authorized (FRN 812245) fund manager founded in 2018 that operates a suite of tax-efficient investment funds targeting early to growth-stage UK life sciences companies. The firm offers four fund vehicles—the o2h human health SEIS Fund (up to 50% income tax relief), the o2h human health EIS Fund (30% income tax relief), the o2h human health Knowledge Intensive EIS Fund (HMRC-approved, higher investment limits), and the o2h Seven Sisters Human Health EIS Growth Fund (£10m target, growth-stage). Minimum subscriptions range from £10,000 to £25,000 and funds target a 20% IRR with a 3–7 year exit horizon, deploying capital into portfolios of 5–10 unquoted or AIM-listed companies per fund.

The firm's operational core combines capital deployment with physical infrastructure at its proprietary 2.7-acre Mill SciTech Park in Cambridge, which provides incubation and co-location for portfolio companies. Deal sourcing is built on what the firm describes as 20+ years of grassroots relationships within the UK biotech community, with approximately 50% of investments made as first investor and 40% sourced from university spinouts. Since 2018, O2h has backed more than 35 portfolio companies spanning oncology, depression, dermatology, fibrosis, infectious disease, anti-ageing, neuroscience, metabolic disease, and AI-enabled drug discovery platforms such as Turbine, AI VIVO, Kuano, CardiaTec, and PhoreMost.

The business model is a standard asset-management revenue structure: recurring management fees on approximately £8.05m of aggregate AUM, supplemented by performance incentives on successful exits. Capital is raised directly from UK-resident high-net-worth individuals (£100k+ income or £250k+ net assets) and self-certified sophisticated investors, with distribution supported by listings on EISA, MICAP, CoInvestor, and GrowthInvest platforms for adviser-led placement. End investors are cautioned via FCA-mandated risk warnings that they may lose their entire investment.

Name

O2h Ventures

Legal name

o2h Ventures Limited

Website

https://o2hventures.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

O2h Ventures is a UK FCA-authorized, biotech-specialist fund manager offering SEIS, EIS, and Knowledge Intensive EIS funds to high-net-worth and sophisticated investors, deploying capital into 35+ early-stage UK life sciences companies from its Mill SciTech Park in Cambridge.

Ownership category

akta.pro rank

Product category

Venture Capital Fund Management

NAICS

Other Financial Vehicles (52599)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare Access & Life Sciences Impact Funds (FSANAJAI)

akta.pro secondary industries

Impact Investment & Development Investment Funds (BPADACAO), Business Services (B2B) Growth Equity (FSANACAD)

Keywords

• Venture capital funds
• Biotech investment management
• SEIS EIS funds
• Life sciences investing
• Tax-efficient investing

Headquarters

HQ city

Hauxton

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Fund Management Fees: Management fees charged on AUM of the managed EIS/SEIS funds. The firm operates multiple funds including SEIS fund, EIS fund, and Knowledge Intensive EIS Growth fund.
2. Performance Incentives: Performance-based fees from successful portfolio exits. The fund aims to exit investments after 3 years to preserve S/EIS tax reliefs.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

O2h Ventures is a biotech-specialist fund manager that raises and manages UK tax-efficient SEIS and EIS investment funds targeting early-stage life sciences and health-tech companies. The firm sources, incubates, and invests in UK biotech ventures from its proprietary 2.7-acre Mill SciTech Park in Cambridge, deploying investor capital across novel therapeutics, AI-enabled drug discovery platforms, enabling services, tools, and digital health technologies.

Product overview

O2h Ventures operates as a biotech-specialist fund manager offering a suite of tax-efficient investment funds targeting early to growth-stage UK life science companies. The product line includes four distinct fund vehicles: the o2h human health SEIS Fund (seed-stage, up to 50% income tax relief), the o2h human health EIS Fund (EIS-qualifying seed stage, 30% income tax relief), the o2h human health Knowledge Intensive EIS Fund (HMRC-approved, higher investment limits), and the o2h Seven Sisters Human Health EIS Growth Fund (growth-stage, £10m target). The funds collectively invest across novel therapeutics, AI-enabled drug discovery platforms, enabling services, tools, and digital health technologies. The portfolio encompasses over 35 companies spanning AI simulation platforms (Turbine, AI VIVO), quantum-AI molecular design (Kuano), cell preservation technology (Atelerix), precision medicine in neuroscience (Monument Therapeutics), gene therapy delivery (ViaNautis), phenotypic screening (PhoreMost), gene editing (Pencil Biosciences), growth factors (Qkine), and various therapeutic development programs in oncology, metabolic health, and anti-aging.

Differentiator

Problem solved

Functional benefit

Products and services

• o2h human health SEIS Fund Seed Enterprise Investment Scheme (SEIS) fund investing in early-stage SEIS-qualifying biotech companies specializing in novel drug discovery, enabling services, tools, and AI technologies. Offers up to 50% income tax relief to UK taxpayers, with minimum subscription of £10,000 and maximum of £200,000. Target fund size of £10m.
• o2h human health EIS Fund Enterprise Investment Scheme (EIS) fund investing in EIS-qualifying seed stage companies covering novel drug discovery along with enabling services, tools and AI technologies. Provides 30% income tax relief with minimum investment of £25,000. AUM of £3.12m with 20% target IRR.
• o2h human health Knowledge Intensive EIS Fund HMRC-approved Knowledge Intensive EIS fund investing in EIS-qualifying biotech companies along with enabling services, tools and AI technologies. Allows up to £2 million investment per tax year with carry-back of EIS tax relief to previous tax years. Current AUM of £3.2m.
• o2h Seven Sisters Human Health EIS Growth Fund Growth-stage EIS fund investing in UK biotech and AI-enabled human health companies developing next-generation therapeutics, drug discovery platforms, and life-science innovation. Target fund size of £10m with minimum investment of £25,000 and no maximum investment.

Quantifiable outcome

• 35+ portfolio companies backed across therapeutic areas including oncology, depression, dermatology, fibrosis, infectious disease, and anti-ageing
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability15 records

Feature2 records

Partnerships

Six partnerships are on record, tiered core.

• JH HealthcoreStrategic or Co-development Partner · 20 April 2026Strategic partnership where JH Health (Saudi Arabia) holds exclusive rights to use and distribute Atelerix's non-cryogenic cell and tissue preservation solutions throughout the Middle East. Partnership includes local high-volume manufacturing and regulatory collaboration supporting Saudi Arabia's biotech infrastructure development.
• Foundation for the National Institutes of Health (FNIH)coreStrategic or Co-development Partner · 23 August 2025Portfolio company Monument Therapeutics partnered with FNIH to launch clinical trial of MT1988 for cognitive impairment in schizophrenia. Trial enrolling 150 participants with FNIH providing prestigious research collaboration infrastructure.
• EISA (Enterprise Investment Scheme Association)coreOthersO2h Ventures is a registered EISA member company, providing credibility and regulatory oversight for EIS fund operations
• MICAPcoreChannel Partner/ Reseller/ DistributorFund finder platform listing O2h Ventures funds for investor access
• CoInvestorcoreChannel Partner/ Reseller/ DistributorInvestment platform providing visibility for O2h Ventures funds to financial advisers and investors
• GrowthInvestcoreChannel Partner/ Reseller/ DistributorPlatform listing O2h Ventures funds for investor access and due diligence

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Parkwalk Advisors: UK EIS fund manager investing in university spinouts across life sciences, deep tech and AI — directly comparable EIS/SEIS distribution model and similar university-spinout thesis. Parkwalk has co-invested alongside o2h Ventures in Qkine.
• Downing Ventures: Operates UK EIS/SEIS funds with significant life-sciences exposure, including co-investment with o2h Ventures in Qkine. Direct competitor for UK HNW capital in biotech-specific tax-efficient vehicles.
• Oxford Capital: UK EIS/SEIS fund manager targeting early-stage companies including health-tech and life sciences. Operates a comparable tax-efficient fund structure serving UK HNW investors with a specialist angle.
• Cambridge Innovation Capital: Cambridge-based venture capital investor focused on deep-tech and life sciences, with a similar specialist mandate to o2h Ventures and overlapping portfolio geographies. Comparable in scale and stage focus on UK university spinouts in biotech.
• Deep Science Ventures: London-based venture studio/fund focused on building science-led companies; co-invested with o2h Ventures in Enedra Therapeutics. Operates a similar specialist UK life-sciences thesis and creates companies in-house.

Broad incumbents

• Octopus Ventures: Larger UK venture platform operating EIS funds (including Titan VCT) with biotech exposure and broader tech focus. Has co-invested alongside o2h Ventures in Pencil Biosciences; significantly larger AUM and broader mandate.
• Albion Capital: Long-established UK investment manager running VCT and EIS funds with healthcare and life-sciences exposure. A broader incumbent offering tax-efficient vehicles with a wider sector mandate than o2h's biotech-only focus.
• IP Group: Listed UK IP commercialisation group with a deep life-sciences portfolio built from university partnerships. Much larger and more diversified, but a benchmark for UK university-spinout-focused biotech investment platforms.
• LifeArc: UK medical-research charity with venture investment activity in life sciences. While not a pure EIS/SEIS competitor, it is a relevant institutional investor operating in the same UK biotech funding ecosystem.

Regional players

• Midven (University of Birmingham Enterprise Fund): Midlands-based UK EIS/VCT fund manager with a life-sciences and deep-tech focus. Operates a comparable tax-efficient fund model and a similar university-spinout sourcing strategy, with regional rather than national reach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@o2hgroup?si=z-8dYJY3FsfQk5Kh
• LinkedInlinkedin.com/company/o2hventures
• Xx.com/o2hventures
• Facebookfacebook.com/o2hlife

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments46 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about O2h Ventures